[Phase I clinical study of 99mTc-ECD].

@article{Kubo1992PhaseIC,
  title={[Phase I clinical study of 99mTc-ECD].},
  author={Atsushi Kubo and Kentaro Nakamura and Yuka Tsukatani and Toshikazu Sanmiya and Suguru Shimizu and Kunihiko Yokoyama and Seiko Hashimoto and Kanji Torizuka},
  journal={Kaku igaku. The Japanese journal of nuclear medicine},
  year={1992},
  volume={29 8},
  pages={
          1019-27
        }
}
A phase I clinical study of 99mTc-L,L-ethyl cysteinate dimer (99mTc-ECD) was carried out in 3 normal volunteers. There was no significant change in vital signs and laboratory parameters attributing to the radiopharmaceutical. 99mTc-ECD was rapidly taken up by the brain, reaching the maximum peak activity within 1 min after the injection and remained relatively constant over several hours. The brain uptake of 99mTc-ECD at 5 min was 5.4 +/- 0.5% which decreased to 5.0 +/- 0.3% by 65 min. 99mTc… CONTINUE READING

Topics from this paper.

Similar Papers

Loading similar papers…